A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs
Status:
Completed
Trial end date:
2010-05-26
Target enrollment:
Participant gender:
Summary
This single arm study will assess the safety and efficacy of tocilizumab in patients with
moderate to severe active rheumatoid arthritis who have an inadequate response to current
non-biologic DMARDs. Patients will receive iv infusions of tocilizumab 8mg/kg every 4 weeks
for a total of 6 infusions, either as monotherapy or in combination with their current
non-biologic DMARDs.